CNS Pharma's Cash Boosted by Offerings Amid Rising R&D, Mounting Losses

TL;DR

**CNSP is burning cash on R&D, but recent stock offerings have temporarily shored up its balance sheet, making it a speculative bet on pipeline success.**

AI Summary

CNS Pharmaceuticals, Inc. reported a net loss of $6,676,281 for the six months ended June 30, 2025, an increase from the $6,075,501 net loss in the same period of 2024. Research and development expenses rose significantly to $4,409,950 for the six months ended June 30, 2025, up from $3,546,974 in the prior year, indicating increased investment in drug candidates. General and administrative expenses decreased slightly to $2,337,095 from $2,526,015. The company's cash and cash equivalents increased substantially to $12,129,873 as of June 30, 2025, from $6,461,378 at December 31, 2024, primarily due to $13,544,685 in proceeds from the sale of common stock and warrants. Total current assets grew to $14,137,820 from $8,658,508, while total current liabilities decreased to $1,382,890 from $2,524,332, improving the company's liquidity. The company executed multiple reverse stock splits, including a 1-for-50 split on February 21, 2025, and a 1-for-12 split on July 22, 2025, to manage share count and potentially maintain NASDAQ listing requirements. Despite improved cash position, management noted substantial doubt about the company's ability to continue as a going concern due to a history of negative cash flows and net losses.

Why It Matters

For investors, CNSP's significant capital raise of $13.5 million from stock and warrant sales is a double-edged sword: it provides crucial liquidity, increasing cash to $12.1 million, but also signals ongoing dilution. The increased R&D spending to $4.4 million is vital for advancing its anti-cancer drug candidates, yet the widening net loss to $6.6 million underscores the high-risk nature of clinical-stage biotechs. Competitively, the ability to secure funding is key in the capital-intensive pharmaceutical sector, but the repeated reverse stock splits could erode investor confidence and make the stock less attractive compared to more stable peers.

Risk Assessment

Risk Level: high — The company explicitly states, "Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company's ability to continue as a going concern." This, coupled with a net loss of $6,676,281 for the six months ended June 30, 2025, and a history of negative cash flows from operations ($8,585,167 used in operating activities), indicates significant financial instability.

Analyst Insight

Investors should approach CNSP with extreme caution, recognizing it as a highly speculative investment. Monitor future financing activities and clinical trial progress closely, as continued dilution is likely and the company's long-term viability hinges on successful drug development and further capital raises.

Financial Highlights

debt To Equity

0.11

revenue

N/A

operating Margin

N/A

total Assets

$ 14,507,875

total Debt

$ 1,382,890

net Income

$ -6,676,281

eps

$ -22.35

gross Margin

N/A

cash Position

$ 12,129,873

revenue Growth

N/A

Key Numbers

• $12.1M — Cash and Cash Equivalents (Increased from $6.46M at Dec 31, 2024, providing short-term liquidity.)
• $6.68M — Net Loss (6 months) (Increased from $6.08M in prior year, indicating widening losses.)
• $4.41M — Research and Development Expenses (6 months) (Increased from $3.55M, reflecting higher investment in drug pipeline.)
• $13.54M — Proceeds from Stock/Warrant Sales (Primary source of cash inflow, significantly boosting cash reserves.)
• 504,413 — Common Shares Outstanding (As of June 30, 2025, after multiple reverse stock splits.)
• 1-for-50 — Reverse Stock Split Ratio (Effective February 21, 2025, reducing share count.)
• 1-for-12 — Reverse Stock Split Ratio (Effective July 22, 2025, further reducing share count.)
• $8.59M — Net Cash Used in Operating Activities (6 months) (Continued high cash burn from operations.)
• $13.12M — Total Stockholders' Equity (Increased from $6.18M at Dec 31, 2024, due to capital raises.)
• $1.38M — Total Current Liabilities (Decreased from $2.52M at Dec 31, 2024, improving short-term financial health.)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — registrant
• A.G.P./Alliance Global Partners (company) — sales agent and placement agent
• NASDAQ Stock Market LLC (regulator) — exchange where common stock is registered
• $12,129,873 (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $6,676,281 (dollar_amount) — net loss for the six months ended June 30, 2025
• $4,409,950 (dollar_amount) — research and development expenses for six months ended June 30, 2025
• $13,544,685 (dollar_amount) — proceeds from sale of common stock and warrants for six months ended June 30, 2025
• June 30, 2025 (date) — end of quarterly period
• February 21, 2025 (date) — effective date of 1-for-50 reverse stock split
• July 22, 2025 (date) — effective date of 1-for-12 reverse stock split

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has noted substantial doubt about the company's ability to continue as a going concern due to a history of negative cash flows and net losses. This is a significant risk for investors as it implies potential inability to meet future obligations.
• Dependence on Drug Development Success [high — operational]: The company's future success is heavily reliant on the successful development and commercialization of its drug candidates. Clinical trial failures or delays can severely impact financial performance and stock value.
• Regulatory Approval Hurdles [high — regulatory]: Obtaining regulatory approval from bodies like the FDA is a lengthy, expensive, and uncertain process. Any setbacks in the approval process for their drug candidates pose a significant risk.
• Dilution from Capital Raises [medium — financial]: The company has relied on issuing common stock and warrants to fund operations, as evidenced by $13.54 million in proceeds during the six months ended June 30, 2025. This can lead to significant dilution for existing shareholders.
• Reverse Stock Split Impact [medium — operational]: The execution of multiple reverse stock splits (1-for-50 on Feb 21, 2025, and 1-for-12 on July 22, 2025) is intended to manage share count and meet listing requirements. However, these actions can sometimes signal underlying financial distress and may not appeal to all investors.

Industry Context

CNS Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of novel treatments for central nervous system diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and securing substantial funding to navigate the path from discovery to market.

Regulatory Implications

The company faces significant regulatory risks associated with the drug development and approval process. Failure to meet stringent FDA requirements or delays in clinical trials can halt development and impact future revenue streams. Compliance with evolving healthcare regulations and reporting standards is also critical.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-02-21: Reverse Stock Split — Executed a 1-for-50 reverse stock split to reduce the number of outstanding shares, potentially impacting share price perception and meeting exchange requirements.
• 2025-05-14: Public Offering Closing — Closed a public offering of common stock and warrants, raising approximately $5 million in gross proceeds to fund operations.
• 2025-06-30: Quarterly Reporting Date — End of the reporting period for the 10-Q filing, providing updated financial status and operational highlights.
• 2025-07-22: Reverse Stock Split — Executed a 1-for-12 reverse stock split, further reducing the number of outstanding shares and continuing efforts to manage share count and compliance.

Glossary

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (Management has explicitly stated substantial doubt about CNS Pharmaceuticals' ability to continue as a going concern, highlighting significant financial risks.)

Additional Paid-in Capital

The amount of capital a company has received from investors in exchange for stock, above the stock's par value. (This account increased significantly to $104.2 million as of June 30, 2025, reflecting substantial capital raised through stock sales.)

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by net income. (The accumulated deficit grew to $91.1 million, underscoring the company's history of operating losses.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of a company's stock, usually to increase the stock's market price. (CNS Pharmaceuticals executed multiple reverse stock splits to manage its share count, impacting the number of shares outstanding and per-share metrics.)

Weighted Average Shares Outstanding

The average number of a company's outstanding shares over a specific period, used to calculate earnings per share. (The weighted average shares outstanding saw a dramatic decrease from 457 in the prior year to 298,776 for the six months ended June 30, 2025, due to reverse stock splits.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, CNS Pharmaceuticals reported a net loss of $6.68 million, an increase from $6.08 million in the prior year, indicating widening losses. Research and development expenses rose to $4.41 million from $3.55 million, reflecting increased investment in drug candidates. While general and administrative expenses saw a slight decrease, the overall operating loss widened. The company's cash position significantly improved to $12.13 million from $6.46 million, primarily due to substantial proceeds from stock and warrant sales, which also boosted total stockholders' equity. Current liabilities decreased, improving liquidity, but the company continues to face going concern uncertainties.

Key Financial Figures

• $0.001 — he registrant's common stock, par value $0.001 per share, as of August 14, 2025 was 57
• $250,000 — xcess of the federally insured limit of $250,000. The amount in excess of the FDIC insur
• $5.2 million — initial aggregate sales price of up to $5.2 million. On July 30, 2024, the Company increase
• $25.0 million — ld under the AGP ATM Sales Agreement to $25.0 million (not including the original $5.2 millio
• $43.5 million — ld under the AGP ATM Sales Agreement to $43.5 million (which amount includes $6.4 million rem
• $6.4 million — to $43.5 million (which amount includes $6.4 million remaining from the $30.2 million set fo
• $30.2 million — ncludes $6.4 million remaining from the $30.2 million set forth above). During the six months
• $15.18 — and one accompanying Common Warrant was $15.18 and the combined purchase price of one
• $15.17 — and one accompanying Common Warrant was $15.17. Subject to certain ownership limitati
• $13.68 — of Common Stock at a price per share of $13.68 and expire five years from Initial Exer
• $68,600 — to receive annual cash compensation of $68,600. As of August 25, 2022, Dr. Waldemar Pr
• $15.0 m — l trial for a licensed product – either $15.0 milli

Filing Documents

• cns_i10q-063025.htm (10-Q) — 445KB
• cns_ex3101.htm (EX-31.1) — 7KB
• cns_ex3102.htm (EX-31.2) — 7KB
• cns_ex3201.htm (EX-32.1) — 3KB
• cns_ex3202.htm (EX-32.2) — 3KB
• 0001683168-25-006162.txt ( ) — 2757KB
• cnsp-20250630.xsd (EX-101.SCH) — 20KB
• cnsp-20250630_cal.xml (EX-101.CAL) — 26KB
• cnsp-20250630_def.xml (EX-101.DEF) — 103KB
• cnsp-20250630_lab.xml (EX-101.LAB) — 244KB
• cnsp-20250630_pre.xml (EX-101.PRE) — 202KB
• cns_i10q-063025_htm.xml (XML) — 254KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Balance Sheets as of June 30, 2025 and December 31, 2024 (unaudited) 3 Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudited) 4 Statements of Stockholders' Equity (Deficit) for the three and six months ended June 30, 2025 and 2024 (unaudited) 5 Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited) 6 Notes to the Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 22

Signatures

Signatures 23 2

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS CNS Pharmaceuticals, Inc. Balance Sheets (Unaudited) June 30, 2025 December 31, 2024 Assets Current Assets: Cash and cash equivalents $ 12,129,873 $ 6,461,378 Deferred offering costs 14,173 20,637 Subscription receivable – 882,539 Prepaid expenses and other current assets 1,993,774 1,293,954 Total current assets 14,137,820 8,658,508 Noncurrent Assets: Prepaid expenses, net of current portion 366,251 36,430 Property and equipment, net 3,804 6,005 Total noncurrent assets 370,055 42,435 Total Assets $ 14,507,875 $ 8,700,943 Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable and accrued expenses $ 1,261,123 $ 2,198,260 Notes payable 121,767 326,072 Total current liabilities 1,382,890 2,524,332 Total Liabilities 1,382,890 2,524,332 Stockholders' Equity (Deficit): Preferred stock, $ 0.001 par value, 416,667 shares authorized and 0 shares issued and outstanding – – Common stock, $ 0.001 par value, 25,000,000 shares authorized and 504,413 and 117,796 shares issued and outstanding, respectively 504 118 Additional paid-in capital 104,225,466 90,601,197 Accumulated deficit ( 91,100,985 ) ( 84,424,704 ) Total Stockholders' Equity (Deficit) 13,124,985 6,176,611 Total Liabilities and Stockholders' Equity (Deficit) $ 14,507,875 $ 8,700,943 See accompanying notes to the unaudited financial statements. 3 CNS Pharmaceuticals, Inc. Statements of Operations (Unaudited) Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Operating expenses: General and administrative $ 1,242,340 $ 1,411,573 $ 2,337,095 $ 2,526,015 Research and development 1,167,045 1,116,562 4,409,950 3,546,974 Total operating expenses 2,409,385 2,528,135 6,747,045 6,072,989 Loss from operations ( 2,409,385 ) ( 2,528,135 ) ( 6,747,045 ) ( 6,072,989 )

financial statements and footnotes

financial statements and footnotes. Common Stock On July 26, 2024, the Company entered into a Sales Agreement (the "AGP ATM Sales Agreement") with A.G.P./Alliance Global Partners ("AGP"). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal, shares of the Company's common stock, par value $0.001 per share with initial aggregate sales price of up to $5.2 million. On July 30, 2024, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to $25.0 million (not including the original $5.2 million). On March 20, 2025, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to $43.5 million (which amount includes $6.4 million remaining from the $30.2 million set forth above). During the six months ended June 30, 2025, the Company has sold 127,582 shares of common stock pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $ 9 million. As of June 30, 2025, the Company has sold 210,230 shares of common stock pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $ 22.8 million. On May 13, 2025, the Company entered into a placement agency agreement (the "Placement Agency Agreement") with A.G.P./Alliance Global Partners (the "Placement Agent") for the public offering by the Company of (i) 27,084 shares of the Company's common stock, (ii) pre-funded warrants to purchase 302,298 shares of common stock (the "Pre-Funded Warrants"); and (iii) Series F Warrants to purchase up to an aggregate of 329,381 shares of common stock (the "Common Warrants"). The Common Warrants and Pre-Funded Warrants are collectively referred to herein as the ("Warrants"). The combined purchase price of one share of Common Stock and one accompanying Common Warrant was $15.18 and the combined purchase price of one Pre-Funded Warrant and one ac